Seven Grand Managers’s Humacyte HUMA Stock Holding History

Seven Grand Managers’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-50,000	Closed	-$156K	–	58
2024 Q1	$156K	Buy	+50,000	New	+$168K	0.08%	44

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Seven Grand Managers's HUMA Position: Q2 2024 in Review

Seven Grand Managers sold out of Humacyte (HUMA) in Q2 2024, closing a stake of 50,000 shares — an estimated $156K sold.

Seven Grand Managers first reported a position in HUMA in Q1 2024 and held it in 1 quarter. The position peaked at $156K in Q1 2024. 123 funds tracked by Wall St. Rank hold HUMA as of Q2 2024.

Seven Grand Managers reported no remaining Humacyte position as of Q2 2024 after selling out during the quarter.
Seven Grand Managers sold 50,000 Humacyte shares in Q2 2024, an estimated $156K.
Seven Grand Managers first reported a position in Humacyte in Q1 2024 and held it in 1 quarter.
Seven Grand Managers's Humacyte position peaked at $156K in Q1 2024.
123 funds tracked by Wall St. Rank held Humacyte as of Q2 2024.

Based on Seven Grand Managers's 13F filing for Q2 2024, filed 14 Aug 2024.